Through our experience conducting more than 230 rare disease studies since 2010, Quintiles understands the challenges inherent in rare disease drug development. Undefined endpoints, limited disease knowledge, complex regulatory pathways and few suitable patients – these are just some aspects of rare disease clinical research that can leave you charting new paths.
With flexible patient-centric approaches tailored to the needs of rare disease studies, Quintiles is an experienced partner who can help you identify and address the complex challenges of rare disease research, to help you speed new treatments to market for patients and their families.
From identifying outcome measures that demonstrate safety and efficacy to generating the real-world evidence that payers are looking for, we are here to offer the specialized scientific, clinical and operational expertise you need to bring rare disease therapeutics to patients and their families.
To learn more, visit quintiles.com/rarediseases